Month: July 2020

ATLANTA, July 13, 2020 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, today announced executive leadership appointments effective July 13, 2020. Jeanine Christian joins DLH as President, Social & Scientific Systems (“S3”), and Jacqueline Everett is appointed as DLH Chief Growth Officer.In her role as President of the Company’s S3 operating unit, Ms. Christian succeeds Kevin Beverly and will lead operations focused on the Public Health and Life Sciences market. Having spent over 20 years in science-based organizations, she most recently led a team of over 300 scientists, clinicians, researchers, and data analysts whose mission it was to translate scientific discovery and technology advances into societal benefits for federal...

Gaithersburg, MD, July 13, 2020 (GLOBE NEWSWIRE) — mPhase Technologies, Inc. (OTCQB: XDSL) (“mPhase” or the “Company”) is providing the following update to highlight significant improvements to its Travel Buddhi platform, which is in final-stage development as an integrated content, planning, booking and engagement solution for global travelers. The Travel Buddhi division is pleased to announce that it is now collaborating with mPhase’s new consumer-oriented technology division, CloseComms, to build an in-destination consumer engagement solution geared toward travelers.This will mark the fourth important component of the Travel Buddhi platform and will be an industry first. This technology integration will give brands tied to the Travel Buddhi platform cross-border portability of their customer engagement programs, via artificial...

Westport, CT, July 13, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the enrollment of adult patients for its Phase II trial for merimepodib, a broad-spectrum, orally administered antiviral drug candidate for the treatment of COVID-19, at four key trial sites. The trial sites are located in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ.Merimepodib is intended to be orally administered and has demonstrated broad-spectrum in-vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures.“Three of our four trial sites where our partners are enrolling patients are in the recognized hot spots of Texas, Arizona, and Florida. The patients in this trial...

MONTREAL, July 13, 2020 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the company’s expansion of its Bioganix CleanCare brand into the Disinfection and Personal Protection Market following successful entry into the hand sanitizing business.EXPANSION INTO DISINFECTION AND PPES MARKETFollowing a successful launch of its hand sanitizing product line, and in view of new demand arising from the ongoing global pandemic, the Company’s wellness brand is expanding its mandate to cover Disinfection and Personal Protection Equipment and Supplies (the “PPES Business”). With the expected introduction of Air Purification and Disinfection System for Home and Office this fall, the Company is also mapping out its entry into disinfection technologies...

SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that it has raised gross proceeds of approximately $90 million through its At-the-Market (ATM) facility with participation based on interest received from RA Capital Management and Invus. The company sold approximately 11.2 million shares at $7.98 per share, the market price at the time of sale. SVB Leerink is acting as lead sales agent and B. Riley FBR is acting as co-sales agent for the ATM facility.The additional funds raised through the ATM facility will support the clinical and preclinical development of Vaxart’s product candidates, to conduct clinical trials, to manufacture its products, and for general...

Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research collaboration with AstraZeneca.The collaboration was initiated in September 2015 to determine whether PCI Biotech’s fimaNAc technology has the potential to enhance the delivery of AstraZeneca’s nucleic acid therapeutic compounds. The evaluation of the potential for a further collaboration now runs to the end of 2020.Contact information:                 Per Walday, CEOpw@pcibiotech.noMobile: +47 917 93 429 About PCI Biotech         PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation...

DALLAS, July 13, 2020 (GLOBE NEWSWIRE) — P10 Holdings, Inc. (OTC: PIOE, also referred to as “P10” or the “Company”) today announced that it is changing its status as a shell company.  Per P10’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 14, 2017, the Company was considered a “shell company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  Effective October 5, 2017, P10 ceased to be a shell company.  The following provides the reasons P10 believes it is no longer a shell company.Rule 12b-2 of the Exchange Act defines a shell company as a company that has (1) no or nominal operations; and, (2) either, (i) no or nominal assets; (ii) assets consisting solely of cash and cash equivalents; or (iii) assets consisting of any amount of cash and cash...

CINCINNATI, July 13, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays.Since the emergence of COVID-19 in January, Meridian has worked side-by-side with molecular diagnostic companies with critical master mixes and enzymes for their COVID-19 molecular diagnostics tests.  These tests are typically ultra-sensitive and can diagnose early in the infection, but they must be carried out by trained technicians in a laboratory, delaying diagnosis.  To meet the critical need for easier, faster and cheaper screening assays, Meridian has launched a highly sensitive and specific pair of monoclonal antibodies...

SALT LAKE CITY, July 13, 2020 (GLOBE NEWSWIRE) — Security National Financial Corporation (NASDAQ-SNFCA) is pleased to announce the lease expansion by Finicity Corporation to 43,598 square feet in Security National’s Center 53 Development Project in Murray, Utah.  Center 53 is Finicity’s corporate headquarters and this expansion has made Finicity the largest tenant in the Center 53 Development.Upon Phase 1 of Center 53 receiving its certificate of occupancy in 2017, Finicity became its first tenant, occupying the second floor of the new building.  As Finicity’s growth has continued, its need for additional space has been apparent, resulting in this second expansion.  With Finicity’s latest expansion, Phase 1 of Center 53 has now achieved 93% occupancy.Founded in 1999, Finicity provides secure, inclusive and innovative financial data-sharing...

NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) — TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 20,940,000 shares of common stock, par value $0.001 per share at an offering price of $0.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $10.5 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about July 15, 2020, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.This offering was made pursuant...